Merck has appointed Maya Martinez-Davis as the new global head of its oncology franchise. Reporting to Merck's Rehan Verjee, chief marketing and strategy officer of its healthcare business, Martinez-Davis (pictured) will be based out of the firm's Massachusetts office. In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell lung cancer therapy, which is expected in 2017. Prior to joining Merck, Ms.Martinez-Davis had spent over a decade at Pfizer, occupying increasingly senior executive roles, most recently of which was as North America regional president, oncology. Meanwhile, Andrew Schiermeier has been appointed as general manager of Merck Serono's immuno-oncology alliance with Pfizer, based in Boston, US. Prior to his three years in the global head of oncology role, Schiermeier served as a chief operating officer of Aura BioSciences, during which time he was also a corporate advisor to Pathogenica, a biotech start-up.